LC28
LC28 is a STAT3 inhibitor with a human STAT3 Ki of 3.92 μM. LC28 targets the DNA-binding domain of STAT3, inhibits STAT3-DNA binding, and suppresses STAT3 signaling. LC28 induces apoptosis and suppresses survival of cisplatin-resistant ovarian cancer cells. LC28 can be used for the research of Cisplatin (HY-17394)-resistant ovarian cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 723746-47-2
- 화학식: C17H13BrClNO2
- 분자량:378.65
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
|
STAT3 3.92 μM (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H1299 | IC50 |
8.1 μM
Compound: LC28
|
Cytotoxicity against human H1299 cells assessed as inhibition of cell survival after 72 hrs by SRB method
Cytotoxicity against human H1299 cells assessed as inhibition of cell survival after 72 hrs by SRB method
|
[PMID: 30145375] |
| SK-OV-3 | IC50 |
3.7 μM
Compound: LC28
|
Cytotoxicity against human SKOV3 cells assessed as inhibition of cell survival after 72 hrs by SRB method
Cytotoxicity against human SKOV3 cells assessed as inhibition of cell survival after 72 hrs by SRB method
|
[PMID: 30145375] |
In Vitro
LC28 (0.01-1000 μM; 72 h) suppresses survival of H1299 non-small cell lung cancer cells with an IC50 of 8.1 μM after 72 h of treatment[1].
LC28 (0.01-1000 μM; 72 h) suppresses survival of SKOV3 ovarian cancer cells with an IC50 of 3.7 μM and cisplatin-resistant SKOV3/DDP ovarian cancer cells with an IC50 of 14.7 μM after 72 h of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human non-small cell lung cancer H1299 cells
-
Concentration:0.01-1000 μM; 5 μM
-
Incubation Time:72 h
-
Result:Suppressed H1299 cell survival with an IC50 of 8.1 μM.
Reduced H1299 cell survival to approximately 20% relative to vehicle control at 5 μM.
-
Cell Line:human ovarian cancer SKOV3 cells, cisplatin-resistant human ovarian cancer SKOV3/DDP cells
-
Concentration:0.01-1000 μM
-
Incubation Time:72 h
-
Result:Suppressed survival of SKOV3 cells with an IC50 of 3.7 μM.
Suppressed survival of cisplatin-resistant SKOV3/DDP cells with an IC50 of 14.7 μM.
-
Cell Line:cisplatin-resistant human ovarian cancer SKOV3/DDP cells
-
Concentration:15 μM, 30 μM (48 h); 15 μM (12 h, 24 h, 48 h); 15 μM (48 h pretreatment prior to IL-6 stimulation)
-
Incubation Time:12 h, 24 h, 48 h; 48 h (pretreatment prior to IL-6 stimulation)
-
Result:Reduced phosphorylation of STAT3 at Tyr705 (with minimal effect on total STAT3 protein levels) in a dose- and time-dependent manner.
Decreased IL-6-induced STAT3 phosphorylation.
Reduced protein and mRNA levels of the STAT3 downstream target genes cyclin D1 and survivin in a dose- and time-dependent manner.
-
Cell Line:cisplatin-resistant human ovarian cancer SKOV3/DDP cells
-
Concentration:15 μM, 30 μM
-
Incubation Time:48 h
-
Result:Increased the percentage of early and late apoptotic SKOV3/DDP cells to 16% relative to untreated cells at 15 μM for 48 h.
Increased the percentage of early and late apoptotic SKOV3/DDP cells to 22% relative to untreated cells at 30 μM for 48 h.
Chemical Information
-
CAS No. 723746-47-2
-
분자량 378.65
-
화학식 C17H13BrClNO2
-
SMILES
O=C(C=CC1=CC=C(Cl)C=C1)C2=CC(Br)=CC=C(NC)C2=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)